Investigating the effect of norepinephrine infusion to prevent hypotension in spinal anesthesia in women candidates for non-emergency caesarean section

Determining the effect of norepinephrine infusion on preventing hypotension in spinal anesthesia in women candidates for non-emergency caesarean section

A clinical trial with a control group, with parallel groups, double-blind, randomized, phase 2 is performed on 60 patients. Random allocation software is used for randomization.

This study is conducted on women who are candidates for caesarean section under spinal anesthesia in the Kausar operating room of Shahid Sadoughi Hospital, Yazd. 10 minutes before spinal anesthesia, the drug under study or placebo is infused to the patient and up to 10 minutes after the birth of the baby. continues. Hemodynamic variables are measured before drug administration and then every 3 minutes until the end of the drug administration and then every 5 minutes until the end of the surgery and recorded in the questionnaire. This study is double-blind and neither the researcher nor the patient knows the type of drug prescribed.

Inclusion criteria: All term pregnant women candidates for non-emergency caesarean surgery aged 20 to 35 and ASA class ll Exit criteria:Lack of patient consent to participate in the study,Severe heart, kidney, lung and liver disease,Pre-eclampsia and eclampsia diseases and,vaginal bleeding and all cases of emergency cesarean section,Use of drugs and psychotropic substances

Intervention group: In this group, norepinephrine is infused at a dose of 0.01 μg per minute from 10 minutes before spinal anesthesia to 10 minutes after the birth of the baby. Control group: In this group, normal saline is infused with the same volume from 10 minutes before spinal anesthesia to 10 minutes after the birth of the baby.

systolic blood pressure; diastolic blood pressure; arterial average; heart rate; Umbilical cord pH; Baby Apgar

In order to randomly allocate 60 eligible applicants, we randomly divide them into two groups of 30 people. For this purpose, we use Random allocation software version 1.0 under Windows to create a sequence, and by using this software we make A list which is specified from 1 to 60 with group A or B treatment By Using this list, we give the first person who is eligible to enter the study, number one and the last person the number 60, then based on the random allocation list and by the software, it is determined which group A or B each person is in. Each drug is placed in a package and the packages are coded and based on the table of random numbers and specified code, the drug is given to patients by a third person who is not involved in evaluating patients and recording results.

Patients and researchers themselves are unaware of which medication the patient has received, in this way, each drug is placed in a package and the packages are coded and based on the table of random numbers and specified code, the drug is given to patients by a third person who is not involved in evaluating patients and recording results.